China Resources Shuanghe Pharmaceutical Co., Ltd. has a glorious history of more than 80 years. It was founded in 1939. It was originally a military pharmaceutical factory in the Taihang Mountain Revolutionary Base and was named the Minglihua Pharmaceutical Factory. In 1949, it moved to Beijing with the army and later renamed Beijing Pharmaceutical Factory. Developed into a large state-owned chemical pharmaceutical comprehensive preparation enterprise, laying the foundation of Beijing's modern chemical pharmaceutical industry; listed on the Shanghai Stock Exchange in 1997, renamed Beijing Shuanghe Pharmaceutical Co., Ltd., and became a cross-regional group based in Beijing and radiating across the country through external expansion; in 2010 It has entered the world's top 500 company under China Resources Group. It was renamed China Resources Double Crane in 2012 and is now one of the business units of China Resources Group's big health field.

The company's main business covers new drug research and development, preparation production, drug sales, raw material production and pharmaceutical equipment, etc. It has rich product line and brand advantages, high-quality product quality and cost control, strong channel and terminal coverage and management capabilities, With international advantages, dynamic team advantages and profound cultural heritage, economic strength, competitive vitality and sustainable development capabilities rank among the forefront of domestic pharmaceutical companies. In 2022, the company achieved operating income of 9.447 billion yuan and net profit of 1.215 billion yuan.

The company actively deploys four major business platforms: general drug business, infusion business, differentiated drug business and innovative drug business, and deeply cultivates chronic diseases, infusion, pediatrics, nephrology, mental/nervity and other fields, and enters the oncology field, No. 0, Fusui The annual sales of 18 key products, including Yue, nifedipine sustained-release tablets, Pivastatin calcium tablets, Tangshiping, BFS infusion, Kelisu, peritoneal dialysate, magnesium valproate sustained-release tablets, exceeded 100 million yuan. It owns trademarks such as "Shuanghe Tu", "Saike" and "Xiangzhong" and has won many honors.

The company accelerates innovation and transformation, builds multiple technology platforms, continuously enriches product clusters, continues to increase R&D investment, actively cooperates with domestic and foreign universities, R&D institutions and pharmaceutical companies to accelerate product acquisition; has first-class domestic production and manufacturing capabilities, 20 companies The production bases are distributed in 14 provinces and cities in the country, including North China, Northwest China, Central China, South China and other regions, and have built an advanced production management system and quality management benchmarks against international first-class standards. The sales network covers 33 provinces, municipalities, autonomous regions and special administrative regions across the country. It has a strong influence in the North China, Jiangsu and Zhejiang and infusion base markets. Some raw materials and preparation products are exported to more than 40 countries in the international market. Through rich product support, thoughtful marketing services, good terminal control capabilities and professionalism The marketing team works together with customers for win-win results.

In the future, China Resources Double Crane will continue to accelerate innovation transformation and quality development, implement China Resources Group's "1246" model, serve the people's livelihood of a great country, build a major weapon, and strive to become a world-class pharmaceutical company trusted by the public and driven by innovation, for the development of the industry and the public. Make greater contributions to health.